Does Semaglutide Reduce Muscle Mass — and How Much Should You Worry?

What the trial data actually showed about lean mass

When researchers looked at body composition in semaglutide studies, the picture was more reassuring than the headline 'losing muscle' fear implies. In STEP 1, participants on 2.4mg semaglutide lost significantly more total weight than those on placebo (around 15% on average) and the majority of that reduction came from fat mass. Lean mass did fall, but as a fraction of overall weight lost, it was smaller than the fat fraction. That pattern matters, because the concern with weight-loss medicines is not that lean mass falls at all (it almost always does when body weight falls substantially) but whether the ratio of fat loss to lean loss is unfavourable.

Subsequent sub-studies and analyses have broadly confirmed this. The NHS medicines page for semaglutide notes that body weight reductions are driven primarily by fat tissue, and professional bodies reviewing the data have drawn similar conclusions. If you want to explore how semaglutide's effect on muscle mass is shaped by the mechanism behind its action on body weight, our overview of how semaglutide reduces weight goes into this in more detail.

Why some lean-mass loss is almost unavoidable, and what puts it in context

It is worth being honest about the biology here. When the body runs a sustained calorie deficit, it draws on both fat stores and some lean tissue for energy. This happens with dietary restriction, with exercise programmes and with any medicine that reduces calorie intake significantly. What differs between interventions is the ratio. Evidence from diet-alone studies suggests that roughly 25–30% of weight lost through calorie restriction alone comes from lean mass. GLP-1 medicines appear to produce a somewhat more favourable ratio, though the exact figure varies across studies and depends heavily on the individual's protein intake, activity level and starting body composition.

There is also an important practical point: people with obesity often carry more lean mass than their BMI suggests, partly because larger frames require more muscle to function. Some reduction in absolute lean mass as weight falls is therefore expected and not automatically harmful. The question your prescriber is asking is whether your functional muscle and metabolic health are protected over the course of treatment, not whether the number on a DEXA scan is identical to where it started. For a focused look at whether semaglutide affects muscle mass specifically in the context of Wegovy, our page on Wegovy and muscle mass covers the detail.

Protein and resistance exercise: the two levers with the best evidence

If you are on semaglutide (or considering it) and you are worried about muscle, two things consistently appear across the evidence as protective: adequate dietary protein and resistance-based physical activity. Higher protein intakes support muscle protein synthesis even during a calorie deficit; the exact gram-per-kilogram target that is right for you depends on your body weight, age and activity level, so it is worth raising with your prescriber or a registered dietitian rather than applying a population average.

Resistance training (weights, bodyweight exercises, resistance bands) sends a signal to the body to preserve muscle even when total calorie intake falls. Aerobic exercise is beneficial for cardiovascular health and general wellbeing, but it does not protect lean mass to the same degree. Some people find that semaglutide's appetite-reducing effect makes it easier to move more (less fatigue, lower physical burden of carrying excess weight) which can actually support activity levels over time. The NHS England guidance on weight-management injections highlights the importance of dietary and lifestyle support alongside treatment, for exactly this reason.

If you would like to read more about the specific question of muscle outcomes on Wegovy, this page on whether you lose muscle mass on Wegovy addresses the most common follow-up questions. And for a broader look at how semaglutide compares with other treatment approaches, our semaglutide information page is a good starting point.

What this means for choosing treatment, and who makes that call

Concern about muscle loss is a fair reason to ask questions, not a reason to rule treatment out. For most people with a BMI that meets the licensed threshold, the metabolic benefits of meaningful weight reduction (on cardiovascular risk, blood-sugar control, joint load and a range of other markers) comfortably outweigh the relatively modest lean-mass changes seen in trials, particularly when protein and activity are prioritised.

That said, the calculus is different for every person. Someone approaching treatment with low baseline muscle mass, sarcopenia risk or a physically demanding job needs a different conversation from someone who lifts regularly and starts treatment well-nourished. This is precisely why semaglutide is a prescription-only medicine: a prescriber reviews your whole picture before any treatment is approved. If you are curious about what that process looks like at a clinician-led service, our team page explains how nume, sorry, how the clinical team at our pharmacy approaches these assessments.

If you are weighing up your options, checking your eligibility through a free consultation is the practical next step, a GPhC-registered prescriber reviews every application the same day, with no algorithm making the decision. It is the kind of conversation where questions about muscle mass are not just welcome; they are exactly what the assessment is designed to explore.